ARTICLE | Emerging Company Profile
Nura reveals neuroprotective lead target, first part of its neurology one-two punch
Nura aims to prevent axon degeneration, preserve neurons starting with an axon death switch
August 5, 2020 12:09 AM UTC
Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen veteran Alpna Seth, the South San Francisco company is developing a small molecule that inhibits SARM1, an axon death switch.
The Column Group, which founded Nura Bio Inc. in 2018, led the round with participation from Samsara BioCapital and Euclidean Capital. TCG’s Tim Kutzkey serves as chairman...
BCIQ Company Profiles
BCIQ Target Profiles